- Home
- SHLS vs REPL Comparison
SHLS vs REPL Comparison
Compare SHLS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- REPL
- Stock Information
- Founded
- SHLS 1996
- REPL 2015
- Country
- SHLS United States
- REPL United States
- Employees
- SHLS N/A
- REPL N/A
- Industry
- SHLS Semiconductors
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- REPL Health Care
- Exchange
- SHLS Nasdaq
- REPL Nasdaq
- Market Cap
- SHLS 660.1M
- REPL 1.1B
- IPO Year
- SHLS 2021
- REPL 2018
- Fundamental
- Price
- SHLS $4.52
- REPL $13.98
- Analyst Decision
- SHLS Buy
- REPL Strong Buy
- Analyst Count
- SHLS 22
- REPL 6
- Target Price
- SHLS $9.93
- REPL $19.83
- AVG Volume (30 Days)
- SHLS 5.7M
- REPL 624.5K
- Earning Date
- SHLS 02-25-2025
- REPL 02-12-2025
- Dividend Yield
- SHLS N/A
- REPL N/A
- EPS Growth
- SHLS N/A
- REPL N/A
- EPS
- SHLS 0.19
- REPL N/A
- Revenue
- SHLS $422,657,000.00
- REPL N/A
- Revenue This Year
- SHLS N/A
- REPL N/A
- Revenue Next Year
- SHLS $11.76
- REPL $1,065.54
- P/E Ratio
- SHLS $23.28
- REPL N/A
- Revenue Growth
- SHLS N/A
- REPL N/A
- 52 Week Low
- SHLS $3.83
- REPL $4.92
- 52 Week High
- SHLS $16.19
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- SHLS 49.40
- REPL 55.54
- Support Level
- SHLS $3.83
- REPL $13.40
- Resistance Level
- SHLS $4.18
- REPL $14.59
- Average True Range (ATR)
- SHLS 0.28
- REPL 0.84
- MACD
- SHLS 0.04
- REPL -0.02
- Stochastic Oscillator
- SHLS 70.20
- REPL 66.52
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.